Harbour Investments Inc. Purchases 833 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Harbour Investments Inc. increased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 18.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,269 shares of the company’s stock after acquiring an additional 833 shares during the quarter. Harbour Investments Inc.’s holdings in Hims & Hers Health were worth $127,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of HIMS. Yong Rong HK Asset Management Ltd bought a new position in Hims & Hers Health in the 4th quarter worth $41,104,000. Principal Financial Group Inc. raised its holdings in Hims & Hers Health by 370.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock worth $33,024,000 after acquiring an additional 1,075,355 shares during the period. Wellington Management Group LLP raised its holdings in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares during the period. Raymond James Financial Inc. bought a new position in Hims & Hers Health in the 4th quarter worth $18,048,000. Finally, Bank of New York Mellon Corp raised its holdings in Hims & Hers Health by 128.7% in the 4th quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company’s stock worth $30,103,000 after acquiring an additional 700,500 shares during the period. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Patrick Harrison Carroll sold 23,287 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the completion of the transaction, the insider now directly owns 209,661 shares of the company’s stock, valued at approximately $7,193,468.91. This represents a 10.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,015,547 shares of company stock worth $36,146,450 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of several research reports. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday, February 26th. Bank of America boosted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. Finally, Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Up 5.8 %

NYSE:HIMS opened at $34.77 on Friday. The firm has a market cap of $7.72 billion, a PE ratio of 79.02 and a beta of 1.37. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The company’s 50-day moving average price is $39.21 and its two-hundred day moving average price is $28.79.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.